Markus Ruegg, PhD
Markus Ruegg is Professor of Neurobiology at the Biozentrum, University of Basel, Switzerland. He studied Biochemistry and Neurobiology at the University of Zurich followed by postdoctoral work at Stanford University. End of 1992, he was appointed as Assistant Professor at the Biozentrum where he works ever since. His scientific interest is the development and the maintenance of the neuromuscular system, which is documented in more than 150 publications. In recent years, his research focuses on signaling pathways important for muscle maintenance and on the development of therapeutic strategies for a rare, congenital muscular dystrophy, called MDC1A or LAMA2 MD. In 2000, Dr. Ruegg helped to set-up MyoContract, now called Santhera Pharmaceuticals Ltd, a biotech company that is dedicated to develop therapies for neuromuscular diseases. In 2019, Santhera and the Ruegg laboratory started a collaboration that aims to develop an AAV-based gene therapy for MDC1A/LAMA2 MD.
Link: http://www.biozentrum.unibas.ch/rueegg
Twitter: @Ruegglab